Navigation Links
Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
Date:6/15/2010

BOSTON, June 15 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has developed a relay lense adapter system for its MammoView® product line. The new system allows the MammoView® scope and endocoupler to join with virtually all video systems currently used in endoscopic procedures. Solos now has the flexibility to market the MammoView® to those customers that previously could not utilize their existing video systems with the MammoView® scope due to incompatibility issues surrounding inconsistent thread sizes between the video camera and endocoupler.

The Company previously developed a new endocoupler with an eye piece for the MammoView® system. Along with its current endocoupler and the eye piece endocoupler, the new adapters will allow the MammoView® scope to be used by the vast majority of the video systems currently in the market place.

"The new adapters allow us to offer the MammoView system to a wider customer base that was previously excluded due to both incompatibility issues with existing video systems as well as the prohibitive additional cost of purchasing a new video system," stated Bob Segersten, President of Solos Endoscopy, Inc.

Throughout the remainder of 2010, the Company will continue its new product development for the MammoView® product line as well as market expansion through its efforts to meet the requirements of the ISO 13485 standard and ultimately obtain the CE Mark and the permission to sell medical devices in the European Union and Canada.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
2. Solos Endoscopy, Inc.s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress
3. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
4. Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line
5. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
6. Solos Endoscopy, Inc. Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Product Line
7. Solos Endoscopy, Inc. Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
8. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
9. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in February Issue of General Surgery News
10. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
11. Solos Endoscopy, Inc. Outlines Marketing Strategy for 2010 Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):